03/10/2026
If you follow sports medicine or regenerative health, you've probably heard about therapeutic peptides like BPC-157, TB-500, and GHK-Cu. They're everywhere right now, from social media to supplement shops.
Here's what we actually know from the peer-reviewed literature:
The preclinical data is interesting. In animal models, BPC-157 has shown improved healing in tendons, ligaments, and muscle. It enhanced MCL ligament repair across multiple routes of administration and accelerated Achilles tendon recovery (Cerovecki et al., J Orthop Res, 2010; Sikiric et al., Pharmaceuticals, 2026).
But here's the honest picture: there are currently zero published human clinical trials for BPC-157 in orthopedic applications. No FDA approval. And a multi-billion-dollar peptide industry that is growing far faster than the evidence supporting it.
A recent editorial in Arthroscopy, one of the top journals in our field, called on orthopedic surgeons to stay informed, because patients and athletes will continue to seek these treatments regardless (DeFoor & Dekker, Arthroscopy, 2024).
And a comprehensive review in JAAOS concluded plainly: "Although preclinical studies are promising, there is a current lack of clinical trials" (Rahman et al., JAAOS Global R&R, 2026).
My take: Dismissing emerging science because it's new isn't evidence-based either. The preclinical data warrants our attention. The clinical gap warrants our patience. I give my patients honest answers about what we know and what we don't, and I'm following this data closely.
When the human trials come, surgeons who've been paying attention will be ready to lead the conversation. The field is moving fast. Don't get left behind.
Swipe through the slides for a quick breakdown of the evidence.